Oruka Therapeutics, Inc.
Moat Score — Oruka Therapeutics, Inc.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Oruka's value rests on patents and licensed IP covering its YTE half-life-extended anti-IL-23p19 (ORKA-001) and anti-IL-17A/F (ORKA-002) antibodies, plus a Halozyme Hypercon subcutaneous-delivery license, but the core antibody IP was licensed in from Paragon Therapeutics rather than discovered in-house, and no patent has yet been validated by an approved, marketed product. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Oruka has no manufacturing scale, no commercial infrastructure, and layers royalty/milestone obligations to both Paragon Therapeutics and Halozyme on top of its own R&D spend, giving it a cost structure that is a drag relative to, not an advantage over, large incumbent biologics makers like AbbVie and Novartis. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With zero approved products and zero revenue, Oruka has no pricing power today; any future pricing power would depend on unproven claims of less-frequent dosing versus entrenched, payer-contracted drugs such as Skyrizi and Cosentyx. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Oruka's business model — individual patient prescriptions for a monoclonal antibody do not become more valuable as more patients or prescribers use the drug. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | No patients or physicians currently use any Oruka product, so no switching costs exist yet; any future switching costs would only emerge after a product is approved and prescribing habits form around it. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The psoriasis/I&I biologics market is large and supports many well-capitalized competitors (AbbVie, J&J, Novartis, Eli Lilly, UCB), so it is not a naturally scale-limited market that would protect an early, sub-scale entrant like Oruka. |